Two African studies demonstrated the potential of HIV treatments by Gilead Sciences to protect heterosexuals from infection. The first study, involving "discordant couples," found that uninfected partners taking a daily dose of Truvada were 73% less likely to contract HIV, while those using Viread were 62% less likely to become infected. In the second study, led by the CDC, Truvada reduced the risk of infection by 63% among young adults who were sexually active.

Related Summaries